Supplementary material BMJ Open

PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	и.	Checklist item	Information reported		Line
	#		Yes	No	number(s)
ADMINISTRATIVE IN	IFORMAT	TON			
Title					
Identification	1a	Identify the report as a protocol of a systematic review			177-178
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			NA
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			74
Authors					
Contact	За	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			35-51
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			332-336
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			NA
Support					
Sources	5a	Indicate sources of financial or other support for the review			337-340
Sponsor	5b	Provide name for the review funder and/or sponsor			NA
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			337-340
INTRODUCTION	-				
Rationale	6	Describe the rationale for the review in the context of what is already known			157-169
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			220-227
		JL			Maral Cambra

1

2

0			Information reported		Line			
Section/topic	#	Checklist item	Yes	No	number(s)			
METHODS								
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review			194-204			
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage			195-200			
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			217-227			
STUDY RECORDS								
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review			244-251			
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			234-242			
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			234-242			
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			222-227			
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			206-215			
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis			252-276			
DATA								
	15a	Describe criteria under which study data will be quantitatively synthesized			281-282			
Synthesis	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)			280-291			
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)			NA			
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			279-291			
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective			NA			
				1 Pion	Tod Central			



Supplementary material BMJ Open

Section/topic	#	Checklist item	Information reported		Line
	#		Yes	No	number(s)
		reporting within studies)			
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	\square		252-276



3